Affiliations: [a] ASST Lodi, Ospedale Maggiore di Lodi, Neurology Unit, Lodi, Italy
| [b] Neuromuscular and Rare Diseases Unit, Department of Neuroscience, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy
| [c] ASST Lodi, Ospedale Maggiore di Lodi, Oncology Unit, Lodi, Italy
| [d] Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Milan, Italy
Correspondence:
[*]
Correspondence to: Anna De Rosa, MD, Neuromuscular and Rare Diseases Unit, Department of Neuroscience,
Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy. Via F. Sforza 35, 20122 Milan (Italy).
Tel.: +39 02 99056504; E-mail: [email protected].
Abstract: Immune-related adverse events (irAE) during the administration of immune-checkpoint inhibitors (ICIs) become more evident due to the increased use of these therapies. To remind the importance of early recognition of this phenomenon, we report a paradigmatic case characterized by severe systemic inflammatory myopathy and severe cardiac involvement that abruptly precipitated in an untoward ending after one single dose of Pembrolizumab.